3 In resource-constrained settings, people living with HIV (PLWH) treated for tuberculosis (TB) 4 despite negative bacteriologic tests have a higher mortality than those treated with positive tests. 5 Many PLWH are treated without bacteriologic testing; their mortality compared to those with 6 bacteriologic testing is uncertain. 7 8 Methods 9 We conducted an observational cohort study among PLWH ≥ 15 years of age who initiated TB 10 treatment at clinical sites affiliated with four regions of the International epidemiology Databases 11 to Evaluate AIDS (IeDEA) consortium from 2012-2014: Caribbean, Central and South America, 12 and Central, East, and West Africa. The primary exposure of interest was the TB bacteriologic 13 test status at TB treatment initiation: positive, negative, or no test result. The hazard for death in 14 the 12 months following TB treatment initiation was estimated using the Cox proportional 15 hazard model, adjusted for patient-and site-level factors. Missing covariates were multiply 16 imputed. 17 18 Results 19 Among 2,091 PLWH included, the median age at TB treatment initiation was 36 years, 44% 20 were female, 53% had CD4 counts ≤ 200 cells/mm 3 , and 52% were on antiretroviral treatment 21 (ART). Compared to patients with positive bacteriologic tests, the adjusted hazard for death was 22 higher among patients with no test results (HR 1.56, 95% CI 1.08-2.26) but not different than 4 23 those with negative tests (HR 1.28, 95% CI 0.91-1.81). Older age was also associated with a 24 higher hazard for death, while being on ART, having a higher CD4 count, West Africa region, 25 and tertiary facility level were associated with lower hazards for death. 26 27 Conclusion 28 PLWH treated for TB with no bacteriologic test results were more likely to die than those treated 29 with positive tests, underscoring the importance of TB bacteriologic diagnosis in resource-30 constrained settings. Research is needed to understand the causes of death among PLWH treated 31 for TB in the absence of positive bacteriologic tests. 5 32 Introduction 33 Although tuberculosis (TB) accounted for 300,000 deaths among people living with HIV 34 (PLWH) in 2017, diagnosing TB in resource-limited settings remains a challenge [1]. In 2017, 35 only 56% of the 5.5 million pulmonary TB cases reported to the World Health Organization 36 (WHO) globally were bacteriologically confirmed (i.e. positive for smear microscopy, culture, or 37 nucleic acid amplification test [NAAT]) [1]. Among studies reporting the autopsy prevalence of 38 TB in HIV-related deaths, TB was prevalent in 37% of deaths, but in half of those cases, TB was 39 not diagnosed by the time of death [2]. The rollout of nucleic acid amplification tests (NAAT)
Short title: Mortality among adults with HIV treated for TB 10 147 included in this model were sex, age, BMI, CD4 count, ART status at TB treatment initiation, 148 TB disease site, IeDEA region, and facility level. These variables were selected a priori because 149 of their associations with adverse TB treatment outcomes in prior studies [21, [36] [37] [38] [39] [40] [41] [42] [43] [44] . The other 150 site variables were not included in the model due to co-linearity with each other and the facility 151 level variable. 152 153 The proportional hazards assumption was assessed using the supremum-type goodness of fit test.
154 The impact of missingness on the observed hazard associations was assessed by refitting the 155 models after imputing missing covariate values. In this analysis, missing values for CD4 count, 156 BMI, and ART status at TB treatment initiation were multiply imputed using the fully 157 conditional specification (FCS), where these covariates were assumed to be jointly distributed 158 [45] . We did not impute missing values for cases with missing facility level, TB disease site, or 159 simultaneously missing BMI, ART status, and CD4 count. Imputation followed Rubin's scheme:
160 missing values were imputed 100 times; Cox proportional hazards models were fit for the 100 161 complete datasets; and, results were pooled to obtain overall effect estimates [46, 47] . Imputation 162 analysis was performed using the PROC MI procedure in SAS [48] . Analyses were performed at 163 the 0.05 alpha level. 164 165 In a secondary analysis comparing the hazard for death among those with any bacteriologic test 166 (positive or negative) vs. no test results, we used logistic regression to build a propensity score 167 model for the log odds of having any bacteriologic test given imbalance of covariates in the test 168 groups (i.e. any test vs. no test). The independent variables included in this model were the same 169 as those used in the primary analysis. Missing values for CD4 count, BMI, and ART status were 170 also multiply imputed. The imputation and propensity model were performed as follows: 1) 171 missing values were imputed separately for those with and without a bacteriologic test; 2) 172 propensity model was fit; 3) stabilized inverse probability weights (IPWs) were constructed 173 using the predicted propensities, checking if the mean of weights was close to one (S3 Table) ; 4) 174 the proportional hazards model was fit for time to death conditional on having any bacteriologic 175 test, weighted by the IPWs to obtain an estimate of log hazards ratio and its robust standard error 176 estimate. These steps were repeated 100 times and the resulting log-hazards ratio estimates and 177 their standard errors pooled using Rubin's rules. Table) . In the odds ratio scale, 305 the adjusted odds of having any test among those with extrapulmonary TB, for example, was 306 45% lower than the odds for those with pulmonary TB (P < 0.0001) (S6 Table) . This model was 307 used to estimate the propensity scores, which were in turn used to compute the stabilized IPWs.
308 For each of the 100 analyses combining multiple imputation and propensity score analysis, the 309 stabilized IPWs were found to have an average close to 1. [20, 21, 40, 41, [55] [56] [57] .
359 360 We did not find a significant difference in the adjusted hazard for death between those treated for 361 TB with any bacteriologic test (positive or negative) versus no test results in the secondary 362 analysis. This finding is consistent with a study in Brazil which found no difference in mortality 363 risk between PLWH who did or did not undergo TB bacteriologic testing [17] . This argues 364 against the notion that the presence of TB bacteriologic testing is a marker of better-resourced 365 sites (and therefore reduced mortality), as patients with a bacteriologic test would have been 366 expected to have a lower mortality than those who were not tested if that were the case. It is 367 possible that patients in both groups had similar survival simply by being engaged in facility-368 based care.
369
370 Finally, we found no significant difference in the hazard for death between those with positive or 371 negative TB bacteriologic tests (Fig 2 and Table 3 ). This lack of significance may in part be 372 related to limited statistical power, as the adjusted hazard for death in those with negative tests
